This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameGusperimus
Accession NumberDB12692
TypeSmall Molecule
GroupsInvestigational
Description

Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIUJ0ZJ76DO9
CAS number98629-43-7
WeightAverage: 387.529
Monoisotopic: 387.295788079
Chemical FormulaC17H37N7O3
InChI KeyIDINUJSAMVOPCM-UHFFFAOYSA-N
InChI
InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)
IUPAC Name
N-[({4-[(3-aminopropyl)amino]butyl}carbamoyl)(hydroxy)methyl]-7-carbamimidamidoheptanamide
SMILES
NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Gusperimus.Approved
AripiprazoleThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Atazanavir.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Gusperimus.Investigational
BendroflumethiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Bendroflumethiazide.Approved
BetamethasoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Gusperimus.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Brexpiprazole.Approved
BumetanideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Buserelin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gusperimus.Approved
CeritinibThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideGusperimus may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorthalidone.Approved
ClozapineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Cortisone acetate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Gusperimus.Approved, Investigational
Cyproterone acetateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Darunavir.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Gusperimus.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Gusperimus.Approved
DesogestrelThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Diazoxide.Approved
DienogestThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dienogest.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Gusperimus.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Gusperimus.Approved
DisopyramideGusperimus may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gusperimus.Approved, Investigational
DrospirenoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Drospirenone.Approved
EpinephrineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EstradiolThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Etacrynic acid.Approved
Ethinyl EstradiolThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Etonogestrel.Approved, Investigational
EverolimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Everolimus.Approved
FingolimodGusperimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Fludrocortisone.Approved
FosamprenavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Gusperimus is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Gusperimus is combined with GI-5005.Investigational
GliclazideGusperimus may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGusperimus may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGusperimus may increase the hypoglycemic activities of Glipizide.Approved
GlyburideGusperimus may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Goserelin.Approved
HistrelinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Iloperidone.Approved
IndapamideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Gusperimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Gusperimus is combined with INGN 225.Investigational
Insulin AspartGusperimus may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGusperimus may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGusperimus may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGusperimus may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGusperimus may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGusperimus may increase the hypoglycemic activities of Insulin Lispro.Approved
LanreotideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lanreotide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Gusperimus is combined with Leflunomide.Approved, Investigational
LeuprolideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Levonorgestrel.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Gusperimus.Approved, Nutraceutical
LopinavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone.Approved
MecaserminGusperimus may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MestranolThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Mestranol.Approved
MethotrimeprazineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Metolazone.Approved
MifepristoneGusperimus may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Gusperimus is combined with Natalizumab.Approved, Investigational
NateglinideGusperimus may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NelfinavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Nelfinavir.Approved
NiacinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NilotinibThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Norgestimate.Approved
OctreotideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Olanzapine.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Gusperimus.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Gusperimus.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gusperimus.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Paliperidone.Approved
PasireotideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pasireotide.Approved
PentamidineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pentamidine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gusperimus.Approved, Investigational
PiperazineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pipotiazine.Approved
PolythiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Polythiazide.Approved
PrednisoloneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Progesterone.Approved, Vet Approved
QuetiapineThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quinethazone.Approved
QuinineGusperimus may increase the hypoglycemic activities of Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Gusperimus is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Gusperimus.Approved
RepaglinideGusperimus may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Gusperimus is combined with CDX-110.Investigational
RisperidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Gusperimus.Approved
SaquinavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Saquinavir.Approved, Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gusperimus.Approved
SirolimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Sirolimus.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Gusperimus is combined with SRP 299.Investigational
SulfadiazineGusperimus may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleGusperimus may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleGusperimus may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibGusperimus may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Gusperimus.Approved, Investigational
TacrolimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemsirolimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Temsirolimus.Approved
TG4010The risk or severity of adverse effects can be increased when Gusperimus is combined with TG4010.Investigational
TipranavirThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Tipranavir.Approved, Investigational
TofacitinibGusperimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideGusperimus may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideGusperimus may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Torasemide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Gusperimus.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Triptorelin.Approved, Vet Approved
VorinostatThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Vorinostat.Approved, Investigational
ZiprasidoneThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL04AA19 — Gusperimus
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentNephritis, Lupus1
2CompletedTreatmentGranulomatosis With Polyangiitis1
3TerminatedTreatmentGranulomatosis With Polyangiitis1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.129 mg/mLALOGPS
logP-0.89ALOGPS
logP-3.2ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)11.37ChemAxon
pKa (Strongest Basic)12.28ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area178.38 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity115.75 m3·mol-1ChemAxon
Polarizability45.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative ParentsAlpha amino acid amides / N-acyl amines / Secondary carboxylic acid amides / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Dialkylamines / Carboximidamides / Alkanolamines / Organopnictogen compounds / Organic oxides
SubstituentsN-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Fatty amide / N-acyl-amine / Fatty acyl / Carboxamide group / Guanidine / Secondary carboxylic acid amide / Alkanolamine / Secondary aliphatic amine
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 17:39 / Updated on September 01, 2017 12:23